Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Laser versus crystallized phenol for pilonidal sinus in adults

Official title: A PROSPECTIVE RANDOMIZED COMPARISON OF LASER ABLATION AND CRYSTALLIZED PHENOL APPLICATION IN PRIMARY UNCOMPLICATED SACROCOCCYGEAL PILONIDAL SINUS DISEASE

Run by Sanliurfa Education and Research Hospital · NCT07701772 · Data updated 2026-11-12

This trial tests whether laser ablation works better than crystallized phenol for adults with a first-time, uncomplicated pilonidal sinus.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment120 (estimated)
SponsorSanliurfa Education and Research Hospital
Government
Locations1 site (Sanliurfa, Şanlıurfa)
StatusRecruiting
StartedJuly 15, 2026
Main results expectedMarch 1, 2027
Study endsMarch 1, 2027
Registry record updatedSeptember 1, 2026
Trial IDNCT07701772 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) with primary, uncomplicated sacrococcygeal pilonidal sinus disease suitable for minimally invasive treatment.

Probably not a fit

Patients with acute abscess, prior pilonidal interventions, recurrent or complex disease, immunosuppression, or inability to attend follow-up may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, randomized study comparing laser ablation to crystallized phenol for adults with primary uncomplicated sacrococcygeal pilonidal sinus disease. Seventy-two? Wait: the protocol plans 120 participants, 60 per arm, randomized 1:1 with allocation concealment. All participants undergo a ~1 cm incision, cleaning of the sinus, and curettage, followed by either laser treatment or phenol application, with possible repeat sessions during healing. The primary endpoint is pain on postoperative day 1, measured by a visual analog scale; key secondary endpoints include 30-day epithelialization, time to epithelialization, day-7 pain, analgesic use duration, return to daily activities/work, early local complications, and 6-month recurrence. Outcomes will inform relative short-term pain and healing trajectories between the two minimally invasive options.

Why it matters

Potential benefit: If successful, this trial could identify the option that offers less early pain and faster healing for pilonidal sinus patients.

How similar studies have gone: Previous research in pilonidal disease has explored laser and chemical treatments separately, with mixed results; this head-to-head randomized trial is designed to clarify comparative effectiveness.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 18 years or older
* Diagnosis of primary chronic sacrococcygeal pilonidal sinus disease
* Uncomplicated disease
* Suitability for minimally invasive treatment
* Provision of written informed consent

Exclusion Criteria:

* Acute pilonidal abscess
* History of pilonidal abscess drainage
* Previous surgical or interventional treatment for pilonidal sinus disease
* Recurrent pilonidal disease
* Complex pilonidal disease or marked lateral extension
* Immunosuppression, chronic steroid use, or systemic conditions that may significantly impair wound healing
* Inability to attend regular follow-up
* Refusal to participate in the study

Where it's running

  • Sanliurfa Education and Research Hospital
    Sanliurfa, Şanlıurfa, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.